Table 3.

ORs and 95% confidence intervals (95% CI) for intrahepatic bile duct (IHBC), gallbladder, cholangiocarcinoma cancers by circulating Se and SePP levels in the EPIC nested case-control study.

Cancer site	No. of ca/co	Matching factorsa OR (95% CI)	Multivariable adjustedb OR (95% CI)
Se, per 20 µg/L
IHBC	36/36	0.70 (0.39, 1.25)	0.42 (0.15, 1.20)
Gallbladderc	41/41	0.50 (0.26, 0.97)	0.55 (0.22, 1.37)
Cholangiocarcinomad	31/31	0.67 (0.37, 1.23)	0.34 (0.10, 1.08)
SePP, per 1.5 mg/L
IHBC	40/40	0.71 (0.43, 1.16)	0.51 (0.21, 1.23)
Gallbladder	44/44	0.69 (0.37, 1.26)	0.33 (0.08, 1.35)
Cholangiocarcinoma	35/35	0.74 (0.45, 1.22)	0.51 (0.23, 1.22)

Abbreviations: EPIC, European Prospective Investigation into Cancer and Nutrition; CI, confidence interval; IHBC, intrahepatic bile duct; OR, incidence rate ratio; Se, selenium; SePP, selenoprotein P.

^aORs and 95% CI estimated by conditional logistic regression conditioned on the matching factors.

^bAdditionally adjusted for body mass index (kg/m2, continuous), waist circumference (cm, continuous), baseline alcohol intake (g/d, continuous), physical activity (METs, continuous), smoking status (never, former, current, unknown), education (none/primary, technical/professional, secondary, university or higher), alcohol intake pattern (never drinkers, former drinkers, drinkers only at recruitment, always drinkers), self-reported diabetes, and total energy intake (kcal/d).

^cGallbladder cancers were also included in the GBTC grouping (see table 2).

^dCholangiocarcinoma cancers were also included in the GBTC (see table 2) and IHBC groupings.